With the recent development of clinical-grade agents targeting the HGF/MET pathway, inhibition of this pathway is currently considered a rational and promising strategy for the treatment of patients with B-cell lymphoma and MM [13,34]. Here, HGF is linked to B-cell non-Hodgkin lymphoma.